- The Indian pharmaceutical market registered 9.6% growth for the quarter ended December 31, much slower than the previous quarter and below expectations, due to lower sales and inventory levels compared to the previous year.
- Cadila Healthcare is recommended as a buy between Rs. 280-310 per share with a 15 day timeframe, as it is expected to report positive quarterly results and its price is trading above the 50 and 200 day moving averages with the RSI trending upward.
- Viewers are advised to do their own research and consult experts before making any investment decisions based on information provided, as all recommendations are for educational purposes only.